Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of dapagliflozin on liver dysfunction, hepatic steatosis, and serum levels of sDPP-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

Trial Profile

Study of dapagliflozin on liver dysfunction, hepatic steatosis, and serum levels of sDPP-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 27 Feb 2019 Results assessing the impact of dapagliflozin on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease, published in the International Journal of Clinical Practice
    • 18 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top